YARW
Yarrow Bioscience Inc
Price Chart
Latest Quote
$28.05
-0.89 (-3.08%)
Current Price
| Previous Close | $28.94 |
| Open | $28.94 |
| Day High | $28.94 |
| Day Low | $26.47 |
| Volume | 27,803 |
Stock Information
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider Ownership | 17.93% |
| Institutional Ownership | 39.62% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $21.72 |
| SMA50 | $19.89 |
| SMA200 | $16.09 |
| RSI | 84.08 |
| ATR | 2.3029 |
| Rel Volume | 0.61 |
Performance History
| Week | nan% |
| Month | nan% |
| Quarter | nan% |
| 6 Months | nan% |
| YTD | nan% |
| Year | nan% |
| 3 Years | nan% |
| 5 Years | nan% |
| 10 Years | nan% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-28 | $28.05 | 28,000 |
| 2026-07-27 | $28.56 | 93,300 |
| 2026-07-24 | $25.45 | 59,064 |
| 2026-07-23 | $26.05 | 19,760 |
| 2026-07-22 | $25.34 | 24,212 |
| 2026-07-21 | $25.20 | 108,202 |
| 2026-07-20 | $22.80 | 44,870 |
| 2026-07-17 | $21.48 | 20,104 |
| 2026-07-16 | $21.68 | 30,746 |
| 2026-07-15 | $21.36 | 43,890 |
| 2026-07-14 | $20.07 | 28,806 |
| 2026-07-13 | $18.57 | 59,040 |
| 2026-07-10 | $18.01 | 321,862 |
| 2026-07-09 | $18.97 | 542 |
| 2026-07-08 | $18.35 | 444 |
| 2026-07-07 | $18.91 | 1,018 |
| 2026-07-06 | $18.85 | 1,708 |
| 2026-07-02 | $19.19 | 10,404 |
| 2026-07-01 | $19.22 | 13,860 |
| 2026-06-30 | $18.37 | 1,186 |
| 2026-06-29 | $18.29 | 2,338 |
About Yarrow Bioscience Inc
Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease. The company was incorporated in 2025 and is based in New York, New York.
đ° Latest News
No news articles available at the moment. Check back later for updates on YARW.
Period:
Loading...
Balance Sheet (Annual)
| Metric | 2025-12-31 |
|---|---|
| Assets | |
| Net Tangible Assets | $28,860,000 |
| Total Assets | $100,407,000 |
| Total Non Current Assets | $407,000 |
| Non Current Deferred Assets | $407,000 |
| Current Assets | $100,000,000 |
| Other Current Assets | $6,000 |
| Receivables | $0 |
| Cash Cash Equivalents And Short Term Investments | $99,994,000 |
| Cash And Cash Equivalents | $99,994,000 |
| Cash Financial | $99,994,000 |
| Liabilities | |
| Total Liabilities Net Minority Interest | $71,547,000 |
| Total Non Current Liabilities Net Minority Interest | $0 |
| Current Liabilities | $71,547,000 |
| Payables And Accrued Expenses | $71,547,000 |
| Payables | $1,534,000 |
| Accounts Payable | $1,534,000 |
| Equity | |
| Common Stock Equity | $-70,990,000 |
| Preferred Stock Equity | $99,850,000 |
| Total Equity Gross Minority Interest | $28,860,000 |
| Stockholders Equity | $28,860,000 |
| Retained Earnings | $-70,994,000 |
| Other | |
| Tangible Book Value | $-70,990,000 |
| Invested Capital | $-70,990,000 |
| Working Capital | $28,453,000 |
| Total Capitalization | $28,860,000 |
| Additional Paid In Capital | $4,000 |
| Capital Stock | $99,850,000 |
| Common Stock | $0 |
| Preferred Stock | $99,850,000 |
| Current Accrued Expenses | $70,013,000 |
Fetched: 2026-07-29